



Published in final edited form as:

Pacing Clin Electrophysiol. 2020 December ; 43(12): 1461–1466. doi:10.1111/pace.14100.

VVI Pacing with Normal QRS duration and Ventricular Function: MOST Trial Findings Relevant to Leadless Pacemakers

Zak Loring, MD, MHS^{1,2}, Rebecca North, MR³, Anne S. Hellkamp, MS², Brett D. Atwater, MD¹, Camille G. Frazier-Mills, MD, MHS¹, Kevin P. Jackson, MD¹, Sean D. Pokorney, MD, MBA¹, Gervasio A. Lamas, MD⁴, Jonathan P. Piccini, MD, MHS^{1,2}

¹Division of Cardiology, Duke University Medical Center, Durham, NC

²Duke Clinical Research Institute, Durham, NC

³Department of Statistics North Carolina State University, Raleigh, NC

⁴Division of Cardiology, Mount Sinai Medical Center, Miami Beach, FL

Abstract

Background: Leadless pacemakers (LPs) provide ventricular pacing without the risks associated with transvenous leads and device pockets. LPs are appealing for patients who need pacing, but do not need defibrillator or cardiac resynchronization therapy. Most implanted LPs provide right ventricular pacing without atrioventricular synchrony (VVIR mode). The Mode Selection Trial in Sinus Node Dysfunction Trial (MOST) showed similar outcomes in patients randomized to dual chamber (DDDR) vs ventricular pacing (VVIR). We compared outcomes by pacing mode in LP-eligible patients from MOST.

Methods: Patients enrolled in the MOST study with an LVEF >35%, QRSd <120ms and no history of ventricular arrhythmias or prior implantable cardioverter defibrillators were included (LP-eligible population). Cox proportional hazards models were used to test the association between pacing mode and death, stroke or heart failure hospitalization and atrial fibrillation (AF).

Results: Of the 2,010 patients enrolled in MOST, 1,284 patients (64%) met inclusion criteria. Baseline characteristics were well balanced across included patients randomized to DDDR (N=630) and VVIR (N=654). Over four years of follow-up, there was no association between pacing mode and death, stroke or heart failure hospitalization (VVIR HR 1.28 [0.92–1.75]). VVIR pacing was associated with higher risk of AF (HR 1.32 [1.08–1.61], p=0.007), particularly in patients with no history of AF (HR 2.38 [1.52–3.85], p<0.001).

Address for Correspondence: Zak Loring, MD, MHS, Department of Medicine, Division of Cardiology, Duke University Medical Center, 2301 Erwin Rd, DUMC 3845, Durham, NC 27710, (p) 919-668-4649, (f) 919-681-9842, zak.loring@duke.edu.

Author contributions:

ZL: concept/design, drafting article, approval of article; RN: data analysis/interpretation, critical revision of article, statistics, approval of article; ASH: data analysis/interpretation, critical revision of article, statistics, approval of article; BDA: critical revision of article, approval of article; CGFM: critical revision of article, approval of article; KPJ: critical revision of article, approval of article; SDP: critical revision of article, approval of article; GAL: data collection, critical revision of article, approval of article; JPP: critical revision of article, approval of article.

Conclusion: In patients without reduced LVEF or prolonged QRS duration who would be eligible for LP, DDDR and VVIR pacing demonstrated similar rates of death, stroke or heart failure hospitalization; however, VVIR pacing significantly increased the risk of AF development.

Keywords

pacemaker; leadless pacing; outcomes; heart failure; atrial fibrillation

Introduction:

Complications occur in approximately 10% of traditional transvenous pacemaker implantations with the majority of complications being lead-related.¹ Leadless pacemakers (LP) are a safe and effective method of ventricular pacing without the need for implantation of transvenous leads and pulse generators.²⁻⁵ Currently, LPs do not have the ability to function as implantable cardioverter-defibrillators (ICDs) or deliver cardiac resynchronization therapy (CRT). Therefore, patients who have a need for a pacemaker and do not meet indications for either ICD or CRT are the ideal candidates for LPs.

First-generation LPs are self-contained pacemakers that provide asynchronous right ventricular (RV) pacing, although a very recently approved second-generation device is able to provide VDD pacing in some patients with AV block.^{6,7} LPs that provide atrial pacing are in development but are not yet commercially available. In patients with sinus node dysfunction, implantation of an LP would provide asynchronous RV pacing only. The effect of pacing mode in patients with sinus node dysfunction was evaluated in the Mode Selection Trial in Sinus Node Dysfunction (MOST), which randomized patients to dual chamber pacing (DDDR mode) or single chamber pacing (VVIR mode). The MOST trial demonstrated similar rates of stroke free survival in both arms; however, DDDR paced patients had lower rates of atrial fibrillation (AF) and heart failure (HF) hospitalizations.⁸ In patients with QRS duration (QRSd) <120ms, a high amount of ventricular pacing in DDDR was also associated with higher rates of AF and HF hospitalizations.⁹ Frequent ventricular pacing has also been associated with the development of pacemaker syndrome among patients with sinus rhythm treated with VVIR pacing.¹⁰ Understanding how pacing mode affects these outcomes in patients without indications for an ICD or CRT will inform clinical decision making regarding the risks and benefits of LP implantation for patients with sick sinus syndrome. In this study, we analyzed patients enrolled in the MOST trial without substantial left ventricular (LV) dysfunction and QRSd <120ms to evaluate the effect of pacing mode on clinical outcomes in a LP-eligible population.

Methods:

Study Population

The details of the MOST trial have been previously published.⁸ Briefly, 2,010 patients with sick sinus syndrome were enrolled at 91 US sites between September 25, 1995 and October 13, 1999 and implanted with a dual-chamber pacing system. Patients were randomized to VVIR or DDDR pacing mode (patient blinded) at time of implantation and were followed four times during the first year and biannually thereafter. To better emulate an LP-eligible

population, we applied additional exclusion criteria. Patients with moderately reduced or unknown LV function at baseline (LV ejection fraction [EF] $\leq 35\%$, or “moderate” or “severe” dysfunction, or LVEF unknown), a personal history of ventricular tachycardia or ventricular fibrillation, or those with a previous ICD implantation were excluded due to their need for defibrillation capabilities from their device. Additionally, patients with a QRSd ≥ 120 ms or unknown were excluded due to their potential need for cardiac resynchronization therapy. After these exclusions were applied, 1,284 patients enrolled from 89 sites remained (630 randomized to VVIR, 654 randomized to DDDR). This study was approved by the Duke University Institutional Review Board.

Outcomes

The primary outcome of interest was the composite of death, stroke, or heart failure (HF) hospitalization. Secondary outcomes included the components of the composite endpoint as well as the diagnosis of pacemaker syndrome, and the first episode of AF. The occurrence of AF subsequent to device implantation was stratified by patient’s history of AF prior to device implantation. Pacemaker syndrome was only reported on patients assigned to VVIR mode. Thus, this outcome was not compared across pacing modes, but rather the rate of pacemaker syndrome in this population is reported.

Statistical Analyses

Demographic and patient baseline characteristics among included patients were compared between patients randomized to VVIR and DDDR pacing modes. Categorical variables were compared using chi-square tests and continuous variables were compared with the Wilcoxon rank sum test. All analyses were conducted using an intention to treat approach.

Outcomes were compared by pacing mode using Kaplan-Meier curves and Cox proportional hazards models adjusting for variables identified as significant predictors of outcomes using backward selection and an inclusion threshold of $\alpha = 0.05$. For the outcome of AF occurrence, independent models were generated for patients with and without a clinical history of AF at time of randomization. A robust covariance estimate was included in each model to account for within site correlation. Because pacing percentage is typically not known at the time of device implantation, it was not included as a covariate in the multivariable Cox models; however, because this variable is known to have a significant impact on the key outcomes of HF hospitalization and AF,⁹ we conducted a sensitivity analysis in which pacing percentage was included in the above described models. Ventricular pacing percentage data was treated as a time-dependent covariate with last recorded value carried forward to the last date of follow up.

Results:

Study Population

Among 1,284 patients with LVEF $>35\%$, QRSd <120 ms and no history of ventricular arrhythmias or prior ICD, 630 were randomized to VVIR mode and 654 were randomized to DDDR mode. Demographics and baseline characteristics by pacing mode are shown in Table 1. The median age was 74 years (interquartile range [IQR] 67–80) and 51.9% of

patients were female. Mild heart failure symptoms (New York Heart Association [NYHA] class I or II) were present in 86.3% of patients. Compared with the overall MOST trial population, this subpopulation had less cardiomyopathy (4.9% vs 11.9%) but was otherwise similar. Baseline characteristics were well balanced by pacing mode with the exceptions of higher rates of cardiomyopathy (6.3% vs 3.5%, $p=0.021$) and diabetes (21.7% vs 17.1%, $p=0.039$) among patients randomized to DDDR mode.

Clinical Outcomes by Pacing Mode

Over four years of follow up, there were 198 deaths, 54 strokes and 112 HF hospitalizations. Of the 630 patients randomized to VVIR mode, 120 (19.0%) developed pacemaker syndrome. A total of 303 (23.6%) patients experienced one of the primary endpoints (death, stroke or HF hospitalization). Event rates according to the randomized pacing mode are shown in Figure 1. The multivariable Cox-proportional hazard model for the primary endpoint was adjusted for Charlson Comorbidity Index,¹¹ age, Karnofsky performance status score,¹² mini-mental state exam score, presence of lower extremity edema, heart rate, sex, prior congestive HF, NYHA class, antiarrhythmic use at admission, and prior myocardial infarction. There was no association between pacing mode and the primary outcome (VVIR hazard ratio [HR]: 1.28 [0.92–1.75], $p=0.14$) (Table 2A). Similarly, no relationship was shown between pacing mode and the individual components of the composite endpoint, including death (HR 1.11 [0.77–1.61]), stroke (HR 1.33 [0.81–2.17]), and HF hospitalization (HR 1.35 [0.94–1.96]).

AF occurred in a total of 313 patients (24.4%), including 66 patients (9.9%) who had no known history of AF. AF event rates are shown for all patients (Figure 2A) and those with no known history of AF (Figure 2B). The multivariable Cox-proportional hazard model for the occurrence of AF was adjusted for prior AF/flutter, mitral regurgitation murmur, weight, hypercholesterolemia, age, prior atrioventricular (AV) block, and hypertension. Among patients with no history of AF, the model was adjusted for Charlson Comorbidity Index, age, hypercholesterolemia, African-American race, prior AV block, and cardiomyopathy. VVIR pacing mode was associated with a higher risk of AF (HR 1.32 [1.08–1.61], $p=0.007$), particularly among those with no history of AF (HR 2.38 [1.52–3.85], $p<0.001$) (Table 2A).

Sensitivity Analysis

Frequency of ventricular pacing data was available in 1,198 (93.3%) of the 1,284 included patients. The average pacing burden in the study population was $65 \pm 33\%$. Patients in the DDDR mode had an average ventricular pacing burden of $74 \pm 31\%$, whereas patients in the VVIR mode had a pacing burden of $55 \pm 34\%$. When the multivariable hazards models were adjusted for pacing burden there were no differences in the primary outcome, death, or stroke (Table 2B); however, there was a higher rate of HF hospitalization among patients randomized to VVIR pacing (HR 1.69 [1.11–2.56], $p=0.02$).

When adjusted for ventricular pacing burden, multivariable models for AF occurrence showed similar trends as the base model. VVIR pacing mode was associated with a higher risk of AF (HR 1.47 [1.12–1.92], $p=0.005$), particularly among those with no history of AF (HR 3.22 [1.96–5.26], $p<0.0001$) (Table 2B).

Discussion:

In this retrospective analysis of the MOST study focused on patients without reduced LVEF or prolonged QRS duration, pacing mode was not associated with the composite endpoint of death, stroke or HF hospitalization. However, VVIR pacing was associated with a higher hazard of AF and a greater than two-fold increase in hazard of the development of new-onset AF. In patients with sick sinus syndrome who might be considered for a LP, VVIR pacing may not influence the risk of death, stroke or HF hospitalization, but may carry an increased risk of AF particularly among those with no known history of AF.

In many respects, LP is an innovation that simplifies device implant and pacing but provides RV-only pacing. Prospective studies of LPs have demonstrated good safety profiles and acute implant success rates with low procedural complication rates; however, there have been no randomized outcome studies comparing single RV LPs to dual chamber devices. Currently, LPs are used primarily to treat patients with persistent atrial fibrillation and bradycardia; however, a significant minority of LPs are implanted for sinus node dysfunction, bradycardia with infrequent pauses or syncope (15% of patients in LEADLESS, 35.4% in LEADLESS-II, 17.5% in the Micra Transcatheter Pacing Study, and 8% in the Micra Post Approval Registry).²⁻⁵ We took advantage of the randomized treatments inherent to the MOST study and examined outcomes in those patients who would have been eligible for RV LP. The results of this analysis in MOST suggest that use of VVIR pacing with LP in this population would likely not have impacted death, stroke or HF hospitalization rates, but may have increased the risk of AF. Interestingly, sick sinus syndrome patients in the DANPACE trial randomized to AAIR pacing also demonstrated higher rates of AF compared with those randomized to DDDR pacing.¹³ The authors of that study hypothesized that this finding was driven by prolonged AV conduction and possibly more AV dyssynchrony in the AAIR arm highlighting the importance of the AV relationship in the risk of developing subsequent AF. In the model controlling for pacing burden, VVIR pacing was associated with a higher hazard of HF hospitalization despite a lower overall pacing burden compared with DDDR pacing; however, this was a sensitivity analysis using data not always available at the time of pacemaker implantation (ventricular pacing burden) and is hypothesis generating. The majority of patients enrolled in these trials and post-approval registries had a history of AF (67% in LEADLESS, 77% in LEADLESS-II, 73% in the Micra Transcatheter Pacing Study, 67% in the Micra Post Approval Registry); however, a substantial minority of patients did not have a history of AF.¹⁴ These patients may be at increased risk for developing AF with a VVIR LP pacing system. Additionally, the lack of an atrial lead may delay identification of subclinical AF which carries a substantial risk of ischemic stroke or systemic embolism.¹⁵

The MARVEL study demonstrated that using an accelerometer based pacing algorithm designed to detect atrial contraction (VDD pacing) in LPs resulted in significantly higher AV synchrony compared to patients with VVI pacing.⁶ The MARVEL-2 study evaluated an updated algorithm which showed an improvement in median AV synchrony from 27% to 94% using VDD pacing compared to VVIR pacing.⁷ We were unable to directly compare VVI pacing to VDD pacing in this study as only seven patients randomized to DDDR had 0% atrial pacing (which would be the equivalent of VDD pacing). Our results reflect a

comparison of VVI pacing and DDDR pacing with an average amount of atrial pacing (58% \pm 32% in this population). While there have not yet been cardiovascular outcomes studies of this algorithm, the results of the present study suggest that maintenance of AV synchrony may help reduce the risk of developing AF. Due to the lower burden of intravascular foreign material, LPs are an attractive option for patients at higher risk for infection (e.g. immunocompromised patients) and those for whom vascular access is of critical importance (e.g. renal failure patients with a need for current or future dialysis). Current generation LPs do not routinely identify AF episodes;¹⁶ therefore, consideration of AF risk when selecting a pacing device and mode is of particular importance in these patients who are often at high risk for thromboembolic events given AF paroxysms may remain undetected and not appropriately treated with anticoagulation therapy.¹⁷

Limitations

This is a sub-study of a randomized trial and the introduction of additional exclusion criteria may have introduced additional confounding. While the balance of baseline characteristics was similar to the trial as a whole, there were differences in rates of cardiomyopathy and diabetes. However, patients randomized to DDDR had more of these comorbidities which would bias the results towards the null. Additionally, the MOST study was conducted before the advent of algorithms designed to reduce RV pacing burden.¹⁸ Modern devices using these algorithms may have even lower RV pacing percentages, which could result in an even larger benefit with DDDR pacing. For patients in the VVIR group, AF incidence was based on clinical presentation with AF; thus, the incidence of asymptomatic AF may be underestimated in this group and the association between VVIR pacing and AF incidence may be more substantial than shown in this study.

Conclusion:

In patients without reduced LVEF or prolonged QRS duration, DDDR and VVIR pacing demonstrated similar rates of death, stroke, and HF hospitalization. VVIR pacing was associated with a significantly higher risk of developing AF, particularly among patients without a history of AF. Atrial-asynchronous ventricular pacing in an LP-eligible population may not affect the risk of death, stroke, or HF hospitalization, but may confer an increased risk of AF development.

Disclosures:

ZL is supported by NIH T32 training grant #5T32HL069749, receives grant support from Boston Scientific, and serves as a consultant to Huxley Medical Inc. RN is supported in part by NIH T32 training grant #HL079896. ASH reports no conflicts of interest. BDA receives grants for clinical research from Abbott and Boston Scientific and serves as a consultant to Abbott, Biotronik, Boston Scientific, Medtronic, Biosense Webster, and Siemens. CGFM reports no disclosures. KPJ receives research support and serves as a consultant for Medtronic. SDP reports research support from Boston Scientific, Bristol-Myers Squibb, Pfizer, and Janssen Pharmaceuticals; consulting/advisory board support from Boston Scientific, Medtronic, Bristol-Myers Squibb, Pfizer, Janssen Pharmaceuticals, Phillips, and Zoll. GAL reports no disclosures. JPP receives grants for clinical research from Abbott, American Heart Association, Boston Scientific, Gilead, Janssen Pharmaceuticals, and the NHLBI and serves as a consultant to Abbott, Allergan, ARCA Biopharma, Biotronik, Boston Scientific, Johnson & Johnson, LivaNova, Medtronic, Milestone, Oliver Wyman Health, Sanofi, Philips, and Up-to-Date.

Abbreviations:

AF	Atrial fibrillation
AV	Atrioventricular
CRT	Cardiac Resynchronization Therapy
EF	Ejection Fraction
HF	Heart failure
HR	Hazard ratio
ICD	Implantable Cardioverter-Defibrillator
IQR	interquartile range
LP	Leadless pacemaker
LV	left ventricular
MOST	Mode Selection Trial in Sinus Node Dysfunction
NYHA	New York Heart Association
RV	Right ventricular

References:

1. Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. *Heart rhythm*. 2012;9(5):728–735. [PubMed: 22182495]
2. Reddy VY, Exner DV, Cantillon DJ, et al. Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker. *The New England journal of medicine*. 2015;373(12):1125–1135. [PubMed: 26321198]
3. Reynolds D, Duray GZ, Omar R, et al. A Leadless Intracardiac Transcatheter Pacing System. *The New England journal of medicine*. 2016;374(6):533–541. [PubMed: 26551877]
4. Roberts PR, Clementy N, Al Samadi F, et al. A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. *Heart rhythm*. 2017;14(9):1375–1379. [PubMed: 28502871]
5. Reddy VY, Knops RE, Sperzel J, et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. *Circulation*. 2014;129(14):1466–1471. [PubMed: 24664277]
6. Chinitz L, Ritter P, Khelae SK, et al. Accelerometer-based atrioventricular synchronous pacing with a ventricular leadless pacemaker: Results from the Micra atrioventricular feasibility studies. *Heart rhythm*. 2018;15(9):1363–1371. [PubMed: 29758405]
7. Steinwender C, Khelae SK, Garweg C, et al. Atrioventricular synchronous pacing using a leadless ventricular pacemaker: Results from the MARVEL 2 study. *JACC: Clinical Electrophysiology*. 2019:1042.
8. Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. *The New England journal of medicine*. 2002;346(24):1854–1862. [PubMed: 12063369]
9. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of

- pacemaker therapy for sinus node dysfunction. *Circulation*. 2003;107(23):2932–2937. [PubMed: 12782566]
10. Link MS, Hellkamp AS, Estes NA 3rd, et al. High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based pacing in the Mode Selection Trial (MOST). *Journal of the American College of Cardiology*. 2004;43(11):2066–2071. [PubMed: 15172414]
 11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases*. 1987;40(5):373–383. [PubMed: 3558716]
 12. Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. *Journal of gerontology*. 1991;46(4):M139–144. [PubMed: 2071835]
 13. Nielsen JC, Thomsen PE, Højberg S, et al. A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. *European heart journal*. 2011;32(6):686–696. [PubMed: 21300730]
 14. Piccini JP, Stromberg K, Jackson KP, et al. Patient selection, pacing indications, and subsequent outcomes with de novo leadless single-chamber VVI pacing. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology*. 2019;21(11):1686–1693.
 15. Healey JS, Connolly SJ, Gold MR, et al. Subclinical Atrial Fibrillation and the Risk of Stroke. *New England Journal of Medicine*. 2012;366(2):120–129.
 16. Garweg C, Sheldon TJ, Chinitz L, Ritter P, Steinwender C, Willems R. Response to atrial arrhythmias in an atrioventricular synchronous ventricular leadless pacemaker: A case report in a paroxysmal atrial fibrillation patient. *HeartRhythm case reports*. 2018;4(12):561–563. [PubMed: 30581731]
 17. Ovbiagele B, Bath PM, Cotton D, Sha N, Diener H-C. Low Glomerular Filtration Rate, Recurrent Stroke Risk, and Effect of Renin–Angiotensin System Modulation. *Stroke*. 2013;44(11):3223–3225. [PubMed: 23988639]
 18. Sweeney MO, Hellkamp AS, Lee KL, Lamas GA. Association of prolonged QRS duration with death in a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation*. 2005;111(19):2418–2423. [PubMed: 15867173]




Figure 1: Product-Limit Survival Curves by Pacing Mode for Death, Stroke or Heart Failure Hospitalization




Figure 2A:
Product-Limit Survival Curves by Pacing Mode for Atrial Fibrillation Episodes among All Patients




Figure 2B:
 Product-Limit Survival Curves by Pacing Mode for Atrial Fibrillation Episodes Among Patients with No Known History of Atrial Fibrillation

Table 1:

Baseline characteristics by pacing mode

Characteristic	Overall N=1,284	VVIR N=630	DDDR N=654	P
Age (years)	74 (67–80)	74 (67–80)	73 (66–79)	0.3839
Female	667 (51.9)	339 (53.8)	328 (50.2)	0.1898
Non-white race	202 (15.7)	96 (15.2)	106 (16.2)	0.6333
Hypertension	789 (61.4)	377 (59.8)	412 (63.0)	0.2455
Hypercholesterolemia	478 (37.4)	231 (36.8)	247 (37.9)	0.7004
Current smoker	115 (9.0)	55 (8.8)	60 (9.2)	0.5406
Prior myocardial infarction	261 (20.3)	117 (18.6)	144 (22.0)	0.1285
Prior heart failure	178 (13.9)	81 (12.9)	97 (14.9)	0.3008
New York Heart Association class I or II heart failure	1,092 (86.3)	545 (87.8)	547 (84.8)	0.1268
Cardiomyopathy	63 (4.9)	22 (3.5)	41 (6.3)	0.0209
Prior stroke	134 (10.4)	60 (9.5)	74 (11.3)	0.2940
Diabetes	250 (19.5)	108 (17.1)	142 (21.7)	0.0387
Chronic Obstructive Pulmonary Disease	125 (9.7)	56 (8.9)	69 (10.6)	0.3153
Percutaneous transluminal coronary angioplasty	158 (12.3)	73 (11.6)	85 (13.0)	0.4360
Coronary-artery bypass grafting	212 (16.5)	105 (16.7)	107 (16.4)	0.8827
Other cardiac surgery	29 (2.3)	16 (2.5)	13 (2.0)	0.5030
Any supraventricular tachycardia	706 (55.0)	337 (53.5)	369 (56.4)	0.2914
Atrial fibrillation	573 (44.6)	267 (42.4)	306 (46.8)	0.1122
Other atrial tachycardia	123 (9.6)	60 (9.5)	63 (9.6)	0.9470
Complete heart block	49 (3.8)	29 (4.6)	20 (3.1)	0.1486
Second-degree heart block	82 (6.4)	38 (6.0)	44 (6.7)	0.6101
Prolonged atrioventricular interval	122 (9.5)	65 (10.3)	57 (8.7)	0.3278
Other heart block	22 (1.7)	12 (1.9)	10 (1.5)	0.6040
Vasovagal syndromes	41 (3.2)	23 (3.7)	18 (2.8)	0.3591

Continuous variables are presented as median (inter-quartile range).

Categorical variables are presented as frequencies (percentages).

Table 2A:

Adjusted Hazard Models (Baseline Variables Only)

Outcome	VVIR HR (95% CI)	P
Primary Outcome	1.28 (0.92–1.75)	0.14
Death	1.11 (0.77–1.61)	0.56
Stroke	1.33 (0.81–2.17)	0.25
HF Hospitalization	1.35 (0.94–1.96)	0.09
AF- All patients	1.31 (1.08–1.61)	0.007
AF- Patients with No AF History	2.38 (1.52–3.85)	0.0002

AF = atrial fibrillation; CI = confidence interval; HF = heart failure; HR = hazard ratio

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2B:

Adjusted Hazard Models (Including % V pacing)

Outcome	VVIR HR (95% CI)	P
Primary Outcome	1.32 (0.97–1.78)	0.07
Death	1.01 (0.74–1.39)	0.94
Stroke	1.33 (0.76–2.33)	0.32
HF Hospitalization	1.69 (1.11–2.56)	0.02
AF- All patients	1.47 (1.12–1.92)	0.005
AF- Patients with No AF History	3.22 (1.96–5.26)	<0.0001

AF = atrial fibrillation; CI = confidence interval; HF = heart failure; HR = hazard ratio